Abstract
Short Retraction Notice International Journal of Clinical Medicine (IJCM) does not meet authors’ publication requirements. This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Please see the article page for more details. The full retraction notice in PDF is preceding the original paper which is marked "RETRACTED".
Highlights
Lung cancer is the leading cause of cancer-related death in the world [1]
epidermal growth factor receptor (EGFR) as a driving gene, plays an important role in the treatment of advanced lung cancer, and EGFR-tyrosine kinase inhibitors (TKI) significantly prolongs the progression-free survival (PFS) of patients with advanced non-small cell lung cancer (NSCLC) who are positive for EGFR mutations [6], and it has become a first-line standard treatment for patients with advanced EGFR mutant positive NSCLC
Statistical analysis showed that the distribution of EGFR gene mutation positive cases in patients with gender, smoking status and histological type were statistically significant (p < 0.01), while the distribution of age, ethnicity, sample type and tumor grade were not statistically significant (p > 0.05)
Summary
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) therapy recently achieved promising successes in NSCLC patients harboring EGFR active mutations [3] [4] [5] significantly prolonging patients’ survival. EGFR as a driving gene, plays an important role in the treatment of advanced lung cancer, and EGFR-TKIs significantly prolongs the progression-free survival (PFS) of patients with advanced NSCLC who are positive for EGFR mutations [6], and it has become a first-line standard treatment for patients with advanced EGFR mutant positive NSCLC. For early NSCLC patients, there is still a high risk of disease recurrence after radical resection [7] [8] [9]. A large proportion of patients die from the recurrence of lung cancer [10] [11]. With the rapid development of targeted therapy, more and more studies have begun to explore the
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
